MindWalk Therapeutics (HYFT) - Long-Term Debt to Capital Coefficient

MindWalk Therapeutics - graphic logo of issuer HYFT

The long-term debt-to-equity ratio demonstrates the debt sustainability of MindWalk Holdings (HYFT), where the value 0.41 describes the current level. MindWalk Holdings is scaling its AI services through partnerships with clinics, accelerating digital diagnostics. Neural networks are automating data collection, replacing a staff of analysts. However, the lack of stable revenue and dependence on investments create significant risks regarding engineer retention.

MindWalk Holdings, Inc. (HYFT): Long-Term Debt to Equity from 09/05/2025 to 11/01/2026
Signature product of MindWalk Holdings

MindWalk Holdings' adaptation to digital sovereignty requirements is reflected in its historical long-term debt-to-equity ratio. This metric determines the company's reliance on external borrowings with maturities exceeding one year. The ratio is calculated as long-term liabilities divided by shareholders' equity. An increase in this indicator signals liquidity risks, while a decrease suggests a potential investment deficit. This serves as a key indicator of the business's financial stability.

Analysis of competing companies

Haleon PLC - Long-Term Liabilities to Equity|Long-Term Debt to Capital KVUE|VRNA (Verona Pharma Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital MENS (Jyong Biotech Ltd)|Long-Term Debt to Capital ligand.com LGND|AMRX - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient PRGO (Perrigo Company PLC)|Alvotech Corp (ALVO) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Liquidia Inc.|GLPG (Galapagos NV) - Long-Term Debt to Capital|Long-Term Debt to Capital anipharmaceuticals.com|Long-Term Debt to Equity Ratio MNKD (MannKind)|AMPH (Amphastar Pharmaceuticals Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Pacira PCRX|ARS Corp (SPRY) - Long-Term Liabilities to Capital|TBPH: Long-Term Debt to Equity Ratio|aquestive.com - Long-Term Loans to Capital Ratio|SCPH: Long-Term Debt to Capital|Tectonic Therapeutic - Long-Term Debt to Capital Coefficient|TNXP (Tonix Pharmaceuticals Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital SXT China SXTC|Long-Term Debt to Equity Eupraxia Pharmaceuticals (EPRX)|BHST (bioharvest.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity eXoZymes EXOZ|ORMP - Long-Term Debt to Equity Ratio|Entera Bio Corp - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital ABVC BioPharma, Inc ABVC|Cumberland Pharmaceuticals (CPIX) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio QNTM|FGEN (FibroGen) - Long-Term Debt to Capital|Long-Term Debt to Capital Ratio TELO (Telomir Pharmaceuticals Inc)|Long-Term Debt to Equity Ratio RANI (Rani Therapeutics)|Long-Term Debt to Equity Ratio synergychc.com SNYR|Long-Term Debt to Capital RLYB (Rallybio)|Long-Term Debt to Capital Lexaria Bioscience Corp LEXX|PULM - Long-Term Debt to Equity|PTHL: Long-Term Debt to Equity|aptorumgroup.com (APM) - Long-Term Debt to Equity|Lyra Therapeutics Inc (LYRA) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio IBO|TNFA: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital YCBD|PRFX (PainReform Ltd) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Altamira Therapeutics Ltd. CYTO|Lipella Pharma (LIPO) - Long-Term Liabilities to Capital|OPTN - Long-Term Debt to Equity|PIRS: Long-Term Debt to Equity|PROC: Long-Term Debt to Capital|Long-Term Debt to Capital Ratio PTPI|QLI (Qilian International Holding Group Limited) - Long-Term Debt to Capital|ACELYRIN Inc. (SLRN) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity TFF Pharmaceuticals (TFFP)